Dashboard
The company has declared Positive results for the last 3 consecutive quarters
- DEBTORS TURNOVER RATIO(HY) Highest at 3.17 times
- NET SALES(Q) Highest at Rs 288.27 cr
- PBDIT(Q) Highest at Rs 48.49 cr.
Stock is technically in a Mildly Bullish range
With ROCE of 13.2, it has a Very Expensive valuation with a 4.2 Enterprise value to Capital Employed
Majority shareholders : Promoters
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
INR 4,292 Cr (Small Cap)
52.00
40
0.02%
0.54
11.29%
6.14
Total Returns (Price + Dividend) 
Latest dividend: 0.10035574092247301 per share ex-dividend date: Aug-28-2026
Risk Adjusted Returns v/s 
Returns Beta
News

Gufic BioSciences Ltd Shows Bullish Momentum Amid Technical Upgrades
Gufic BioSciences Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underpinned by improvements across key technical indicators including moving averages, Bollinger Bands, and the MACD, signalling renewed investor interest in this small-cap pharmaceutical and biotechnology player.
Read More
Gufic BioSciences Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
Gufic BioSciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a nuanced market sentiment. While the company’s Mojo Grade has improved from Sell to Hold as of 29 June 2026, recent price movements and technical indicators reveal a complex interplay of bullish and bearish signals that investors should carefully analyse.
Read More
Gufic BioSciences Ltd Hits Intraday Low Amid Price Pressure on 16 Nov 2026
Gufic BioSciences Ltd experienced a notable intraday decline on 16 Nov 2026, touching a low of Rs 400.65, down 15.04% from previous levels, reflecting significant price pressure despite a broadly positive market environment.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
16-Nov-2026 | Source : BSENewspaper advertisement of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30 2026 is attached herewith
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
16-Nov-2026 | Source : BSEIntimation of Audio Recording of Earnings Conference Call held on November 16 2026 at 04:30 p.m. is attached herewith
Announcement under Regulation 30 (LODR)-Investor Presentation
14-Nov-2026 | Source : BSEInvestor Presentation is attached herewith
Corporate Actions 
No Upcoming Board Meetings
Gufic BioSciences Ltd has declared 10% dividend, ex-date: 28 Aug 26
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 5 Schemes (3.03%)
Held by 24 FIIs (0.45%)
Jayesh Pannalal Choksi (24.62%)
Motilal Oswal Financial Services Ltd (3.32%)
14.06%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 10.52% vs 3.57% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 5.20% vs 1.87% in Jun 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 13.22% vs -0.71% in Sep 2024
Growth in half year ended Sep 2025 is -29.87% vs -2.76% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 12.59% vs 0.51% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -31.68% vs -6.29% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 15.15% vs 1.63% in Mar 2025
YoY Growth in year ended Mar 2026 is -7.81% vs -19.14% in Mar 2025